Stay Alert for Low-Dose Rivaroxaban for Coronary or Peripheral Artery Disease

December 2018

You'll see a new rivaroxaban (Xarelto) 2.5 mg dose for patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD).

Reps will call this a "vascular" dose. It's approved for BID use WITH aspirin 81 mg/day to reduce CV events in chronic CAD or PAD patients.

But don't expect it to be popular. Most patients will stick with aspirin alone...the margin of benefit of adding rivaroxaban is small.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote